Complications of apheresis in children

@article{Michon2007ComplicationsOA,
  title={Complications of apheresis in children},
  author={Bruno Michon and Albert Moghrabi and Rochelle Winikoff and St{\'e}phane Barrette and Mark L. Bernstein and Josette Champagne and Michèle David and Michel Duval and Heather Hume and N Michelle Robitaille and Andr{\'e} B{\'e}lisle and Martin A. Champagne},
  journal={Transfusion},
  year={2007},
  volume={47}
}
BACKGROUND: Although the frequency of complications in adults undergoing therapeutic apheresis is low, there are little data in children. 
View on Wiley
ncbi.nlm.nih.gov
142 Citations
Highly Influential Citations
6
Background Citations
41
Methods Citations
2
Results Citations
6

142 Citations

Epidemiology of therapeutic apheresis with a multidisciplinary approach at a high volume pediatric center
Therapeutic apheresis (TA) is used inconsistently in pediatric populations. We seek to define our multidisciplinary institutional practice.
An international survey of paediatric apheresis practice
TLDR
Increased attention must be paid to paediatric patients with conditions for which apheresis is indicated, as evidence‐based medicine advances the field of therapeutic Apheresis.
Utility and safety of plasma exchange in paediatric neuroimmune disorders
Our aim was to ascertain the indications, side effects, and outcomes in children receiving therapeutic plasma exchange (TPE) for neurological disorders.
Regional citrate anticoagulation with calcium replacement in pediatric apheresis
The objective of this retrospective analysis was to present our single‐center experience with intravenous (IV) calcium replacement and regional citrate anticoagulation in pediatric apheresis therapy…
Therapeutic Apheresis in Children: Special Considerations
TLDR
The focus of this review is to highlight the disease processes commonly treated with therapeutic apheresis in children, and to address the technical considerations pertinent to the provision of safe and effective apheresIS in the pediatric setting.
A safe therapeutic apheresis protocol in paediatric patients weighing 11 to 25 kg
TLDR
A 3‐year experience with children weighing 11–25 kg at a large academic medical centre is reported, finding that detailed protocols for small children are lacking, and often are performed using guidelines shown to work in larger patients.
Efficacy and safety of therapeutic plasma exchange by using apheresis devices in pediatric atypical hemolytic uremic syndrome patients
TLDR
Therapeutic plasma exchange in atypical hemolytic uremic syndrome patients is considered as first line treatment as per current ASFA guidelines, but there is very limited data available in the literature regarding efficacy and safety of TPE procedures in pediatric aHUS patients.
Safety and efficacy of autologous mononuclear cell and stem cell apheresis in very low‐weight children—Experience at a single center
Apheresis in children with low body weight is technically limited by their tolerance of the extracorporeal blood volume.
The ABC of apheresis
TLDR
A brief overview on general principles, indications and complications of apheresis is given.
Therapeutic plasma exchange for life‐threatening pediatric disorders
TLDR
Evaluating the tolerance of TPE in pediatric patients found it to be an effective treatment in life‐threatening pediatric disorders.
...
...

References

SHOWING 1-10 OF 29 REFERENCES
Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura‐hemolytic‐uremic syndrome
TLDR
The morbidity of plasma exchange treatment has become more important with the increased frequency of diagnosis and improved survival of thrombotic thromBocytopenic purpura‐hemolytic‐uremic syndrome.
Techniques, indications, and toxicity of therapeutic hemapheresis in children
  • D. Kasprisin
  • Medicine, Biology
    Journal of clinical apheresis
  • 1989
Although therapeutic hemapheresis has grown dramatically in the past decade, its utilization and popularity in pediatrics remain limited. The lack of well‐defined indications for treatment and…
[Complications with plasma exchange].
The value of plasma exchange in the treatment of Guillain-Barré syndrome is well established, but in Japan patients often receive double-filtration plasmapheresis or immunoadsorption therapy. In this…
An overview of therapeutic apheresis in pediatrics
  • D. Galacki
  • Medicine, Biology
    Journal of clinical apheresis
  • 1997
TLDR
Diversional activities appropriate for the child's developmental age are provided to allay anxiety, to divert attention, and to elicit cooperation.
Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura‐hemolytic uremic syndrome
TLDR
The morbidity and mortality of catheter placement and PE are important considerations when PE treatment for clinically suspected TTP-HUS is anticipated.
Therapeutic apheresis in low weight patients: technical feasibility, tolerance, compliance, and risks.
  • C. Stefanutti, A. Lanti, G. Isacchi
  • Medicine, Biology
    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • 2004
Therapeutic apheresis in Sweden: update of epidemiology and adverse events.
  • R. Norda, B. Stegmayr
  • Medicine
    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • 2003
[Apheresis tolerance and acceptability in the child weighing 30 kg or less, with the exception of infants].
TLDR
Over the ten past years, the authors performed 336 apheresis among 51 children who were 19 months to 15 years old (10 to 30 kg body weight) and obtained a very good tolerance and acceptability.
Complications of plasma exchange in thrombotic thrombocytopenic purpura‐hemolytic uremic syndrome: a study of 78 additional patients
TLDR
Over 6 years, over 6 years the authors have observed 54 major complications, including 3 deaths, related to PE in 42 of 149 (28 percent) consecutive patients treated for clinically suspected TTP-HUS, and these observations are essential to understand the risks of PE.
Protein A column therapy for a patient refractory to platelet transfusions undergoing allogeneic hematopoietic stem cell transplantation
Protein A column therapy for a patient refractory to platelet transfusions undergoing allogeneic hematopoietic stem cell transplantation
...
...